ARCALIS

About ARCALIS

ARCALIS, Inc. operates as a specialized contract development and manufacturing organization (CDMO) focused on messenger RNA (mRNA) vaccines and therapeutics. It was established in 2021 as a strategic joint venture between Axcelead, Inc., Japan's pioneering drug discovery platform company, and Arcturus Therapeutics, a U.S.-based clinical-stage mRNA medicines company. This venture leverages Arcturus's deep expertise in mRNA manufacturing technologies to address the sector's complex challenges. The company's President and CEO is Dr. Satoshi Takamatsu, a veteran with over 30 years of experience in the CDMO and life sciences industries at companies like Ajinomoto, Fujifilm, and AGC. He leads ARCALIS with the goal of establishing a premier Japanese bio-CDMO that advances new therapeutic modalities for global health.

The company's business model is centered on providing comprehensive, one-stop services to a diverse clientele that includes pharmaceutical firms, biotech companies, and academic institutions worldwide. ARCALIS offers an integrated suite of services that span the entire product lifecycle, from initial drug discovery support and CMC (Chemistry, Manufacturing, and Controls) development to manufacturing of investigational drugs and commercial-scale production. This end-to-end capability is designed to accelerate the research, development, and commercialization of mRNA-based medicines for its clients. Its service portfolio includes tailored mRNA design, plasmid DNA synthesis, LNP formulation, and fill-and-finish services.

A significant milestone for ARCALIS was the completion of its cGMP-compliant mRNA drug substance manufacturing facility in Minamisoma City, Fukushima, in July 2023. This plant is equipped with state-of-the-art systems and has the capacity to produce up to 5kg of mRNA annually, featuring four independent manufacturing rooms to support multiple client projects simultaneously. The company achieved another major achievement in 2024 with the first commercial production of a self-amplifying mRNA vaccine. To further enhance its integrated manufacturing value chain, ARCALIS is expanding its Minamisoma campus with a drug product facility, slated for completion by 2026, and a technology development facility to follow in 2027, supported by grants from the Japanese government aimed at strengthening the nation's vaccine production capabilities.